The clinical use of BonAlive® granules in benign bone tumour surgery is specifically supported by a long-term randomised prospective trial. The results clearly showed that the long-term performance of BonAlive® granules is comparable to autograft. The clinical trial extended up to 14-year follow-up in benign bone tumour surgery.
BonAlive® granules produces a high but balanced local bone turnover by stimulating new bone formation through osteostimulation*. The proven performance of BonAlive® granules shows that it is a well-tolerated and safe bone graft substitute, also in paediatric patients.
For further details see references.